First patient dosed in the phase 2a part of Medivir's study with fostrox in combination with Lenvima
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that the first patient with hepatocellular carcinoma (HCC) has started treatment in phase 2a with the candidate drug fostroxacitabine bralpamide (fostrox) in combination with Lenvima[®].In Medivir's ongoing phase 1b/2a study, fostrox is given in combination with two other drugs, either with Lenvima[®], a tyrosine kinase inhibitor, or with Keytruda[®], an anti-PD-1 checkpoint inhibitor. The study is an